Risk Factor Analysis for Coronary Atherosclerosis Measured by MDCT

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2012 by Korea University.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
K. M. Choi, Korea University
ClinicalTrials.gov Identifier:
NCT01589224
First received: April 24, 2012
Last updated: May 7, 2012
Last verified: April 2012
  Purpose

Coronary MDCT (multi-detector computed tomography) has been useful screening imaging modality for the coronary artery disease. Recently, novel adipokines and hepatokines as well as various inflammatory markers have been known as direct regulators of atherosclerosis. Therefore, the investigators examine the correlation of various metabolic risk factors including adipokines and hepatokines with coronary atherosclerosis measured by coronary MDCT in apparently healthy people.


Condition
Atherosclerosis
Metabolic Syndrome

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Korea University:

Primary Outcome Measures:
  • relation of adipokines and hepatokines with coronary atherosclerosis measured by MDCT [ Time Frame: 3month ] [ Designated as safety issue: No ]
    to examine the correlation of serum concentration of various adipokine such as adiponectin, resistin, A-FABP with coronary atheroslcerosis measured by MDCT as AGATSTON score, modified Gensini score


Secondary Outcome Measures:
  • relation of adipokines and hepatokines with coronary atherosclerosis measured by MDCT [ Time Frame: 3months ] [ Designated as safety issue: No ]
    to examine the correlation of serum concentration of various hepatokines such as FGF-21, fetuin- A and selenoprotein P with coronary atheroslcerosis measured by MDCT as AGATSTON score, modified Gensini score

  • the correlation of various inflammatory markers with coronary atherosclerosis [ Time Frame: 3months ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: May 2012
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Healthy people

  Eligibility

Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Apparently healthy people who underwent medical routine check up in Korea Helath Promotion Center.

Criteria

Inclusion Criteria:

  • Apparently healthy people who underwent medical routine check up in Korea Health Promotion Center.
  • age > 20 years

Exclusion Criteria:

  • History of cardiovascular disease (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)
  • Diabetes
  • Stage 2 hypertension
  • Severe renal or hepatic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01589224

Contacts
Contact: Hye Jin Yoo, MD.Ph.D 822-2626-3045 deisy21@naver.com
Contact: Kyung Mook Choi, MD.Ph.D 822-2626-3043 medica7@gmail.com

Locations
Korea, Republic of
korea University Guro Hospital Recruiting
Seoul, Korea, Republic of
Contact: Hye Jin Yoo, MD.Ph.D    822-2626-3045    deisy21@naver.com   
Principal Investigator: Kyung Mook Choi, MD.Ph.D         
Sponsors and Collaborators
Korea University
  More Information

No publications provided

Responsible Party: K. M. Choi, Professor, Korea University
ClinicalTrials.gov Identifier: NCT01589224     History of Changes
Other Study ID Numbers: KoreaHealth_MDCT
Study First Received: April 24, 2012
Last Updated: May 7, 2012
Health Authority: South Korea: Institutional Review Board

Additional relevant MeSH terms:
Arteriosclerosis
Atherosclerosis
Metabolic Syndrome X
Arterial Occlusive Diseases
Cardiovascular Diseases
Glucose Metabolism Disorders
Hyperinsulinism
Insulin Resistance
Metabolic Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on October 22, 2014